Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: A systematic review - Abstract

OBJECTIVES: To review cases of multidrug-resistant (MDR) Gram-negative bacillus urinary tract infections (UTIs) treated with tigecycline and the literature related to this subject.

METHODS: We performed a systematic review of the literature identifying patients with MDR Gram-negative bacillus UTIs treated with tigecycline.

RESULTS: Fourteen cases describing treatment of UTIs caused by MDR Gram-negative bacilli with tigecycline are reviewed. Favourable clinical outcomes were noted in 11 of 14 cases. An initial favourable microbiological outcome was noted in 12 cases. Post-treatment cultures in two cases were positive for tigecycline-resistant organisms.

CONCLUSIONS: The clinical efficacy of tigecycline for treatment of UTIs has not been extensively evaluated. Based on the available literature, tigecycline appears to have efficacy in some patients with MDR Gram-negative bacillus UTIs. Further research in this area is needed to fully elucidate the role of tigecycline in treating such patients.

Written by:
Brust K, Evans A, Plemmons R.   Are you the author?
Division of Infectious Disease, Scott & White Healthcare, Texas A&M Health Science Center College of Medicine, Temple, TX; Department of Pharmacy, Scott & White Healthcare, Temple, TX, USA.   USA

Reference: J Antimicrob Chemother. 2014 Oct;69(10):2606-10.
doi: 10.1093/jac/dku189

PubMed Abstract
PMID: 24879669

UroToday.com Infections Section